Roche receives FDA De Novo authorization for cobas pro i 601 platform with Ionify Gabapentin assay
Roche received FDA De Novo authorization for its cobas pro i 601 platform and Ionify Gabapentin assay, adding therapeutic drug monitoring to its U.S. mass spectrometry menu.
Roche has received U.S. Food and Drug Administration (FDA) De Novo authorization for the cobas pro i 601 platform with the Ionify Gabapentin assay, components of its cobas Mass Spec solution.
Designed to bring advanced mass spectrometry testing into routine clinical laboratories, the solution combines the analytical capabilities of mass spectrometry with an automated, standardized workflow – expanding Roche's diagnostic menu into therapeutic drug monitoring.
Authorized through the De Novo pathway, the Ionify Gabapentin assay adds a therapeutic drug monitoring application to a U.S. menu that includes 25-Hydroxy Vitamin D total and steroid hormone testing assays, such as estradiol and 17-Hydroxyprogesterone. Roche continues to develop additional clinical mass spectrometry assays to broaden the menu over time. Roche will leverage a Predetermined Change Control Plan (PCCP), to drive and accelerate future clinical mass spectrometry menu expansion while still maintaining rigorous safety and quality standards. The authorized PCCP includes the expansion of up to 22 Ionify assays on the cobas pro i 601 platform as PCCP requirements are met. These additional assays are not yet available and will be introduced in the future as applicable requirements are met.